Literature DB >> 10729127

Evidence for recombination of live, attenuated immunodeficiency virus vaccine with challenge virus to a more virulent strain.

B R Gundlach1, M G Lewis, S Sopper, T Schnell, J Sodroski, C Stahl-Hennig, K Uberla.   

Abstract

Live, attenuated immunodeficiency virus vaccines, such as nef deletion mutants, are the most effective vaccines tested in the simian immunodeficiency virus (SIV) macaque model. In two independent studies designed to determine the breadth of protection induced by live, attenuated SIV vaccines, we noticed that three of the vaccinated macaques developed higher set point viral load levels than unvaccinated control monkeys. Two of these vaccinated monkeys developed AIDS, while the control monkeys infected in parallel remained asymptomatic. Concomitant with an increase in viral load, a recombinant of the vaccine virus and the challenge virus could be detected. Therefore, the emergence of more-virulent recombinants of live, attenuated immunodeficiency viruses and less-aggressive wild-type viruses seems to be an additional risk of live, attenuated immunodeficiency virus vaccines.

Entities:  

Mesh：

Substances：

Year:  2000        PMID： 10729127      PMCID： PMC111861          DOI： 10.1128/jvi.74.8.3537-3542.2000

Source DB:  PubMed          Journal:  J Virol        ISSN： 0022-538X            Impact factor:   5.103


  29 in total

1.  Importance of the nef gene for maintenance of high virus loads and for development of AIDS.

Authors:  H W Kestler; D J Ringler; K Mori; D L Panicali; P K Sehgal; M D Daniel; R C Desrosiers
Journal:  Cell       Date:  1991-05-17       Impact factor: 41.582

2.  Repair and evolution of nef in vivo modulates simian immunodeficiency virus virulence.

Authors:  A M Whatmore; N Cook; G A Hall; S Sharpe; E W Rud; M P Cranage
Journal:  J Virol       Date:  1995-08       Impact factor: 5.103

3.  A partially attenuated simian immunodeficiency virus induces host immunity that correlates with resistance to pathogenic virus challenge.

Authors:  B L Lohman; M B McChesney; C J Miller; E McGowan; S M Joye; K K Van Rompay; E Reay; L Antipa; N C Pedersen; M L Marthas
Journal:  J Virol       Date:  1994-11       Impact factor: 5.103

4.  A formalin-inactivated whole SIV vaccine confers protection in macaques.

Authors:  M Murphey-Corb; L N Martin; B Davison-Fairburn; R C Montelaro; M Miller; M West; S Ohkawa; G B Baskin; J Y Zhang; S D Putney
Journal:  Science       Date:  1989-12-08       Impact factor: 47.728

5.  Animal model for the therapy of acquired immunodeficiency syndrome with reverse transcriptase inhibitors.

Authors:  K Uberla; C Stahl-Hennig; D Böttiger; K Mätz-Rensing; F J Kaup; J Li; W A Haseltine; B Fleckenstein; G Hunsmann; B Oberg
Journal:  Proc Natl Acad Sci U S A       Date:  1995-08-29       Impact factor: 11.205

6.  Pathogenicity of live, attenuated SIV after mucosal infection of neonatal macaques.

Authors:  T W Baba; Y S Jeong; D Pennick; R Bronson; M F Greene; R M Ruprecht
Journal:  Science       Date:  1995-03-24       Impact factor: 47.728

7.  Cellular immune response of rhesus monkeys infected with a partially attenuated nef deletion mutant of the simian immunodeficiency virus.

Authors:  U Dittmer; T Nisslein; W Bodemer; H Petry; U Sauermann; C Stahl-Hennig; G Hunsmann
Journal:  Virology       Date:  1995-10-01       Impact factor: 3.616

8.  vpr deletion mutant of simian immunodeficiency virus induces AIDS in rhesus monkeys.

Authors:  J Hoch; S M Lang; M Weeger; C Stahl-Hennig; C Coulibaly; U Dittmer; G Hunsmann; D Fuchs; J Müller; S Sopper
Journal:  J Virol       Date:  1995-08       Impact factor: 5.103

9.  Multivariate models for predicting progression to AIDS and survival in human immunodeficiency virus-infected persons.

Authors:  S P Blatt; W F McCarthy; B Bucko-Krasnicka; G P Melcher; R N Boswell; J Dolan; T M Freeman; J M Rusnak; R E Hensley; W W Ward
Journal:  J Infect Dis       Date:  1995-04       Impact factor: 5.226

10.  In vitro T cell function, delayed-type hypersensitivity skin testing, and CD4+ T cell subset phenotyping independently predict survival time in patients infected with human immunodeficiency virus.

Authors:  M J Dolan; M Clerici; S P Blatt; C W Hendrix; G P Melcher; R N Boswell; T M Freeman; W Ward; R Hensley; G M Shearer
Journal:  J Infect Dis       Date:  1995-07       Impact factor: 5.226
View more
  24 in total

1.  Pathogenic simian/human immunodeficiency virus SHIV(KU) inoculated into immunized macaques caused infection, but virus burdens progressively declined with time.

Authors:  P S Silverstein; G A Mackay; S Mukherjee; Z Li; M Piatak; J D Lifson; O Narayan; A Kumar
Journal:  J Virol       Date:  2000-11       Impact factor: 5.103

2.  In vitro evolution of a highly replicating, doxycycline-dependent HIV for applications in vaccine studies.

Authors:  G Marzio; K Verhoef; M Vink; B Berkhout
Journal:  Proc Natl Acad Sci U S A       Date:  2001-05-15       Impact factor: 11.205

3.  Essential role for virus-neutralizing antibodies in sterilizing immunity against Friend retrovirus infection.

Authors:  Ronald J Messer; Ulf Dittmer; Karin E Peterson; Kim J Hasenkrug
Journal:  Proc Natl Acad Sci U S A       Date:  2004-08-05       Impact factor: 11.205

4.  Near full-length genomic characterization of a HIV type 1 BC recombinant strain from Manipur, India.

Authors:  Roni Sarkar; Kamalesh Sarkar; N Brajachand Singh; Y Manihar Singh; Sekhar Chakrabarti
Journal:  Virus Genes       Date:  2012-06-19       Impact factor: 2.332

Review 5.  Using death to one's advantage: HIV modulation of apoptosis.

Authors:  T M Ross
Journal:  Leukemia       Date:  2001-03       Impact factor: 11.528

6.  Macaques vaccinated with simian immunodeficiency virus SIVmac239Delta nef delay acquisition and control replication after repeated low-dose heterologous SIV challenge.

Authors:  Matthew R Reynolds; Andrea M Weiler; Shari M Piaskowski; Holly L Kolar; Ann J Hessell; Madelyn Weiker; Kim L Weisgrau; Enrique J León; W Eric Rogers; Robert Makowsky; Adrian B McDermott; Rosanne Boyle; Nancy A Wilson; David B Allison; Dennis R Burton; Wayne C Koff; David I Watkins
Journal:  J Virol       Date:  2010-06-30       Impact factor: 5.103

7.  Early protection against pathogenic virus infection at a mucosal challenge site after vaccination with attenuated simian immunodeficiency virus.

Authors:  Klara Tenner-Racz; Christiane Stahl Hennig; Klaus Uberla; Heribert Stoiber; Ralf Ignatius; Jonathan Heeney; Ralph M Steinman; Paul Racz
Journal:  Proc Natl Acad Sci U S A       Date:  2004-02-17       Impact factor: 11.205

Review 8.  Viral vaccines and CTL response.

Authors:  Stacie N Woolard; Uday Kumaraguru
Journal:  J Biomed Biotechnol       Date:  2010-03-31

9.  Immunization of rhesus macaques with a DNA prime/modified vaccinia virus Ankara boost regimen induces broad simian immunodeficiency virus (SIV)-specific T-cell responses and reduces initial viral replication but does not prevent disease progression following challenge with pathogenic SIVmac239.

Authors:  Helen Horton; Thorsten U Vogel; Donald K Carter; Kathy Vielhuber; Deborah H Fuller; Tim Shipley; James T Fuller; Kevin J Kunstman; Gerd Sutter; David C Montefiori; Volker Erfle; Ronald C Desrosiers; Nancy Wilson; Louis J Picker; Steven M Wolinsky; Chenxi Wang; David B Allison; David I Watkins
Journal:  J Virol       Date:  2002-07       Impact factor: 5.103

10.  Role of complement and antibodies in controlling infection with pathogenic simian immunodeficiency virus (SIV) in macaques vaccinated with replication-deficient viral vectors.

Authors:  Barbara Falkensammer; Barbara Rubner; Alexander Hiltgartner; Doris Wilflingseder; Christiane Stahl Hennig; Seraphin Kuate; Klaus Uberla; Stephen Norley; Alexander Strasak; Paul Racz; Heribert Stoiber
Journal:  Retrovirology       Date:  2009-06-21       Impact factor: 4.602
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.